Mee Young Chang, Courtney Smith, James B DuHadaway, Jennifer R Pyle, Janette Boulden, Alejandro Peralta Soler, Alexander J Muller, Lisa D Laury-Kleintop, George C Prendergast
Indoleamine 2,3-dioxygenase (IDO) modifies adaptive immunity, in part by determining the character of inflammatory responses in the tissue microenvironment. Small molecule inhibitors of IDO are being developed to treat cancer, chronic infections and other diseases, so the systemic effects of IDO disruption on inflammatory phenomena may influence the design and conduct of early phase clinical investigations of this new class of therapeutic agents. Here, we report cardiac and gastrointestinal phenotypes observed in IDO deficient mice that warrant consideration in planned assessments of the safety risks involved in clinical development of IDO inhibitors...
December 15, 2011: Cancer Biology & Therapy